HGHongri Gong

Hongri Gong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hongri Gong has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Weiwei Wang

    Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China

    10 shared publications
  • Zihe Rao

    Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, China

    10 shared publications
  • Shan Zhou

    State Key Laboratory of Medicinal Chemical Biology and College of Life Sciences, Nankai University, Tianjin, China

    8 shared publications
  • Yuying Zhang

    State Key Laboratory of Medicinal Chemical Biology and College of Life Sciences, Nankai University, Tianjin, China

    8 shared publications
  • Luke William Guddat

    The University of Queensland

    7 shared publications
  • Yan Gao

    Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China

    7 shared publications

Latest Publications

  • Top Cited Papers

    Inhibition of M. tuberculosis and human ATP synthase by BDQ and TBAJ-587

    by Yuying Zhang, Yuezheng Lai, Shan Zhou, Ting Ran, Yue Zhang, Ziqing Zhao, Ziyan Feng, Long Yu, Jinxu Xu, Kun Shi, et al.

    Bedaquiline (BDQ), a first-in-class diarylquinoline anti-tuberculosis drug, and its analogue, TBAJ-587, prevent the growth and proliferation of Mycobacterium tuberculosis by inhibiting ATP synthase1,2. However, BDQ also inhibits human ATP synthase3. At present, how these compounds interact with either M. tuberculosis ATP synthase or human ATP synthase is unclear. Here we present cryogenic electron microscopy structures of M. tuberculosis ATP synthase with and without BDQ and TBAJ-587 bound, and human ATP synthase bound to BDQ. The two inhibitors interact with subunit a and the c-ring at the leading site, c-only sites and lagging site in M. tuberculosis ATP synthase, showing that BDQ and TBAJ-587 have similar modes of action. The quinolinyl and dimethylamino units of the compounds make extensive contacts with the protein. The structure of human ATP synthase in complex with BDQ reveals that the BDQ-binding site is similar to that observed for the leading site in M. tuberculosis ATP synthase, and that the quinolinyl unit also interacts extensively with the human enzyme. This study will improve researchers’ understanding of the similarities and differences between human ATP synthase and M. tuberculosis ATP synthase in terms of the mode of BDQ binding, and will allow the rational design of novel diarylquinolines as anti-tuberculosis drugs.


  • Top Cited Papers

    Structure of the human ATP synthase

    by Yuezheng Lai, Yuying Zhang, Shan Zhou, Jinxu Xu, Zhanqiang Du, Ziyan Feng, Long Yu, Ziqing Zhao, Weiwei Wang, Yanting Tang, et al.


  • Open Access

    Structure of the human respiratory complex II

    by Zhanqiang Du, Xiaoting Zhou, Yuezheng Lai, Jinxu Xu, Yuying Zhang, Shan Zhou, Ziyan Feng, Long Yu, Yanting Tang, Weiwei Wang, et al.

    Human complex II is a key protein complex that links two essential energy-producing processes: the tricarboxylic acid cycle and oxidative phosphorylation. Deficiencies due to mutagenesis have been shown to cause mitochondrial disease and some types of cancers. However, the structure of this complex is yet to be resolved, hindering a comprehensive understanding of the functional aspects of this molecular machine. Here, we have determined the structure of human complex II in the presence of ubiquinone at 2.86 Å resolution by cryoelectron microscopy, showing it comprises two water-soluble subunits, SDHA and SDHB, and two membrane-spanning subunits, SDHC and SDHD. This structure allows us to propose a route for electron transfer. In addition, clinically relevant mutations are mapped onto the structure. This mapping provides a molecular understanding to explain why these variants have the potential to produce disease.


  • Discovery of 1-hydroxy-2-methylquinolin-4(1H)-one derivatives as new cytochrome bd oxidase inhibitors for tuberculosis therapy

    by Yang Zhou, Min Shao, Weiwei Wang, Chen-Yi Cheung, Yu Wu, Hang Yu, Xianglong Hu, Gregory M. Cook, Hongri Gong, Xiaoyun Lu


  • Deciphering a novel chloramphenicols resistance mechanism: Oxidative inactivation of the propanediol pharmacophore

    by Jiayu Zhang, Chao Yang, Jiahui Hu, Yiting Zhang, Yuezheng Lai, Hongri Gong, Fangliang Guo, Xiaoyan Li, Lin Ye, Bing Li


  • Open Access

    Structure of Mycobacterium tuberculosis cytochrome bcc in complex with Q203 and TB47, two anti-TB drug candidates

    by Shan Zhou, Weiwei Wang, Xiaoting Zhou, Yuying Zhang, Yuezheng Lai, Yanting Tang, Jinxu Xu, Dongmei Li, Jianping Lin, Xiaolin Yang, et al.

    Pathogenic mycobacteria pose a sustained threat to global human health. Recently, cytochrome bcc complexes have gained interest as targets for antibiotic drug development. However, there is currently no structural information for the cytochrome bcc complex from these pathogenic mycobacteria. Here, we report the structures of Mycobacterium tuberculosis cytochrome bcc alone (2.68 Å resolution) and in complex with clinical drug candidates Q203 (2.67 Å resolution) and TB47 (2.93 Å resolution) determined by single-particle cryo-electron microscopy. M. tuberculosis cytochrome bcc forms a dimeric assembly with endogenous menaquinone/menaquinol bound at the quinone/quinol-binding pockets. We observe Q203 and TB47 bound at the quinol-binding site and stabilized by hydrogen bonds with the side chains of QcrBThr313 and QcrBGlu314, residues that are conserved across pathogenic mycobacteria. These high-resolution images provide a basis for the design of new mycobacterial cytochrome bcc inhibitors that could be developed into broad-spectrum drugs to treat mycobacterial infections.


  • Open Access

    Cryo-EM structure of mycobacterial cytochrome bd reveals two oxygen access channels

    by Weiwei Wang, Yan Gao, Yanting Tang, Xiaoting Zhou, Yuezheng Lai, Shan Zhou, Yuying Zhang, Xiuna Yang, Fengjiang Liu, Luke W. Guddat, et al.

    Cytochromes bd are ubiquitous amongst prokaryotes including many human-pathogenic bacteria. Such complexes are targets for the development of antimicrobial drugs. However, an understanding of the relationship between the structure and functional mechanisms of these oxidases is incomplete. Here, we have determined the 2.8 Å structure of Mycobacterium smegmatis cytochrome bd by single-particle cryo-electron microscopy. This bd oxidase consists of two subunits CydA and CydB, that adopt a pseudo two-fold symmetrical arrangement. The structural topology of its Q-loop domain, whose function is to bind the substrate, quinol, is significantly different compared to the C-terminal region reported for cytochromes bd from Geobacillus thermodenitrificans (G. th) and Escherichia coli (E. coli). In addition, we have identified two potential oxygen access channels in the structure and shown that similar tunnels also exist in G. th and E. coli cytochromes bd. This study provides insights to develop a framework for the rational design of antituberculosis compounds that block the oxygen access channels of this oxidase.


  • Open Access

    Structure of mycobacterial cytochrome bcc in complex with Q203 and TB47, two anti-TB drug candidates

    by Shan Zhou, Weiwei Wang, Xiaoting Zhou, Yuying Zhang, Yuezheng Lai, Yanting Tang, Jinxu Xu, Xiaolin Yang, Luke W. Guddat, Quan Wang, et al.

    Pathogenic mycobacteria pose a sustained threat to global human health. Recently, cytochrome bcc complexes have gained interest as targets for antibiotic drug development. However, there is currently no structural information for the cytochrome bcc complex from these pathogenic mycobacteria. Here, we report the structures of M. tuberculosis cytochrome bcc alone (2.68 Å resolution) and in complex with clinical drug candidates Q203 (2.67 Å resolution) and TB47 (2.93 Å resolution) determined by single-particle cryo-electron microscopy. M. tuberculosis cytochrome bcc forms a dimeric assembly with endogenous menaquinone/menaquinol bound at the quinone/quinol binding pockets. Q203 and TB47 are bound to the quinol-binding site. Hydrogen bonds are formed between the inhibitor and the side chains of QcrB Thr313 and QcrB Glu314, residues that are conserved across pathogenic mycobacteria. These high-resolution structures provide a basis for the design of new mycobacterial cytochrome bcc inhibitors that could be developed into broad spectrum drugs to treat mycobacterial infections.


  • Open Access

    Cryo-EM structure of Mycobacterium smegmatis DyP-loaded encapsulin

    by Yanting Tang, An Mu, Yuying Zhang, Shan Zhou, Weiwei Wang, Yuezheng Lai, Xiaoting Zhou, Fengjiang Liu, Xiuna Yang, Hongri Gong, et al.

    Significance: Tuberculosis, caused by Mycobacterium tuberculosis , remains a major global public health problem. Deciphering the complex biology of M. tuberculosis will aid in the development of new therapeutics to combat this pathogen. Encapsulins, naturally encapsulating specific cargo proteins, are a recently discovered class of smaller proteinaceous compartments found in bacteria and archaea and needed for essential physiological processes. Here, we report the structural and mechanistic characterization of a native DyP-packaging encapsulin from the Mycobacterium smegmatis , a model system for M. tuberculosis . Our results contribute to the understanding of the assembly and physiological role of the encapsulin systems and provide a rational framework for antituberculosis drug design.


  • Open Access

    Architecture of the mycobacterial succinate dehydrogenase with a membrane-embedded Rieske FeS cluster

    by Xiaoting Zhou, Yan Gao, Weiwei Wang, Xiaolin Yang, Xiuna Yang, Fengjiang Liu, Yanting Tang, Sin Man Lam, Guanghou Shui, Lu Yu, et al.

    Significance: Targeting energy metabolism in Mycobacterium tuberculosis has emerged as a new paradigm in antituberculosis drug discovery. Succinate dehydrogenase is considered the regulator of respiration in M. tuberculosis . Mycobacteria contains two different succinate dehydrogenase enzymes designated Sdh1 and Sdh2. Sdh1 has recently been identified as a new class of succinate dehydrogenase. In this study, we have determined M. smegmatis Sdh1 structures alone and in the presence of ubiquinone-1, revealing that Sdh1 has a novel electron transfer pathway and a unique substrate-binding site. These data show that the structure of M. tuberculosis Sdh1 is significantly different by comparison with the human counterpart making a good antituberculosis drug target.